Stamford Pharmaceuticals Inc., a clinical-stage biotechnology company developing science-driven immune therapies focused on cutaneous and visceral cancers, today announced the engagement of Dr Jacque Banchereau as Chief Scientific Officer.

Dr Banchereau, PhD, has studied the human Immune system for more than four decades, both in academic and Pharma/Biotech research centers. At the Schering-Plough/DNAX Laboratory for Immunological Research in Lyon, he focused on the discovery and characterization of numerous human cytokines and the biology of human B-cells and dendritic cells (DCs). At the Baylor Institute for Immunology Research in Dallas, which he founded, he pursued human DC biology and the therapeutic use of DCs in cancer and infectious diseases. In the field of inflammation, he contributed to studies on the role of type I interferon in systemic lupus erythematosus and IL-1 in systemic onset juvenile idiopathic arthritis, which led to the treatment of this unmet medical need. As CSO at Roche in New Jersey, he oversaw the discovery and development unit in the areas of virology and inflammation. At the Jackson Laboratory for Genomic Medicine in Connecticut, he built a human immunology research program and ran a laboratory studying autoimmune diseases, responses to vaccination and the role of alternative splicing in cancer. Most recently Dr Banchereau served as the Chief Science Officer (CSO) at Immunai (New York). Dr Banchereau completed his Ph.D. in biochemistry at the University of Paris in 1980.

Press Release: Stamford Pharmaceuticals Inc announces Dr Jacques Banchereau at Chief Scientific Officer.